Howland Robert H
J Psychosoc Nurs Ment Health Serv. 2016 Jul 1;54(7):21-4. doi: 10.3928/02793695-20160616-09.
Antidepressant, atypical antipsychotic, and hallucinogen drugs mediate their actions in part by interactions with the serotonin-2A (5HT2A) receptor. Serotonergic hallucinogen drugs, such as psilocybin, bind most potently as agonists at the 5HT2A receptor, producing profound changes in perception, mood, and cognition. Some of these drugs have been or are currently being investigated in small Phase 2 studies for depression, alcoholism, smoking cessation, anxiety, and posttraumatic stress disorder. However, unlike the synergistic effects of combining antidepressant and atypical antipsychotic drugs, the potential therapeutic effects of hallucinogen drugs may be attenuated by the concurrent use of these medications because antidepressant and atypical antipsychotic drugs desensitize and/or down-regulate 5HT2A receptors. This finding has important implications for optimizing the potential therapeutic use of hallucinogen drugs in psychiatry. [Journal of Psychosocial Nursing and Mental Health Services, 54(7), 21-24.].
抗抑郁药、非典型抗精神病药和致幻剂药物部分通过与5-羟色胺-2A（5HT2A）受体相互作用来介导其作用。血清素能致幻剂药物，如裸盖菇素，作为5HT2A受体的激动剂结合最为有效，会在感知、情绪和认知方面产生深刻变化。其中一些药物已经或正在小型2期研究中用于治疗抑郁症、酗酒、戒烟、焦虑症和创伤后应激障碍。然而，与联合使用抗抑郁药和非典型抗精神病药的协同效应不同，同时使用这些药物可能会减弱致幻剂药物的潜在治疗效果，因为抗抑郁药和非典型抗精神病药会使5HT2A受体脱敏和/或下调。这一发现对于优化致幻剂药物在精神病学中的潜在治疗用途具有重要意义。[《心理社会护理与精神卫生服务杂志》，54(7)，21 - 24。]
